{"id":"diamorphine-or-morphine","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Drowsiness and sedation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Dependence and tolerance"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs activate mu opioid receptors, which are G-protein coupled receptors found throughout the brain, spinal cord, and peripheral tissues. This activation inhibits the release of neurotransmitters involved in pain signaling and modulates descending pain pathways, resulting in potent analgesic effects. Diamorphine (heroin) is a prodrug that is rapidly converted to morphine and 6-monoacetylmorphine in the body, providing faster onset of action.","oneSentence":"Diamorphine and morphine are opioid agonists that bind to mu opioid receptors in the central and peripheral nervous system to reduce pain perception and produce analgesia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:44.509Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe acute pain"},{"name":"Chronic cancer pain"},{"name":"Acute myocardial infarction pain"},{"name":"Dyspnea in acute pulmonary edema"}]},"trialDetails":[{"nctId":"NCT03976258","phase":"","title":"Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2017-07-14","conditions":"HIV Infection, Opioid-use Disorder, Cardiovascular Diseases","enrollment":190},{"nctId":"NCT02700217","phase":"NA","title":"Does Adding Spinal Anaesthesia to a General Anaesthetic Technique Influence Readiness for Discharge in Patients Having Hand Assisted Laparoscopic Live Donor Nephrectomy","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2016-03-16","conditions":"Surgery","enrollment":101},{"nctId":"NCT02033707","phase":"PHASE1","title":"Effects of Hallucinogens and Other Drugs on Mood and Performance","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-04","conditions":"Healthy","enrollment":20},{"nctId":"NCT00000273","phase":"PHASE2","title":"A Laboratory Model for Heroin Abuse Medications - 8","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"1995-08","conditions":"Heroin Dependence, Opioid-Related Disorders, Substance-Related Disorders","enrollment":8},{"nctId":"NCT02598856","phase":"PHASE1","title":"Bioavailability of Nasal Naloxone and Injected Naloxone Compared","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2016-03","conditions":"Drug Overdose","enrollment":22},{"nctId":"NCT00710385","phase":"PHASE3","title":"Abuse Liability of Suboxone Versus Subutex","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-09","conditions":"Opioid-related Disorders","enrollment":19},{"nctId":"NCT00723177","phase":"PHASE2","title":"Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-10","conditions":"Opioid-Related Disorders","enrollment":30},{"nctId":"NCT01570699","phase":"","title":"Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-12","conditions":"Opioid-related Disorders, Opiate Dependence, Opiate Addiction","enrollment":87},{"nctId":"NCT02210260","phase":"NA","title":"Pain Relief After Colorectal Surgery: Spinal Combined With Painbuster® vs Painbuster® Alone.","status":"COMPLETED","sponsor":"York Teaching Hospitals NHS Foundation Trust","startDate":"2013-09","conditions":"Colorectal Cancer","enrollment":79},{"nctId":"NCT01447212","phase":"PHASE3","title":"Study to Assess Longer-term Opioid Medication Effectiveness (SALOME)","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-12","conditions":"Opioid Dependence, Heroin Dependence","enrollment":202},{"nctId":"NCT01174927","phase":"PHASE1","title":"Effects of Diacetylmorphine (DAM) on Brain Function and Stress Response","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2010-03","conditions":"Opiate","enrollment":60},{"nctId":"NCT00268814","phase":"PHASE3","title":"The German Project of Heroin Assisted Treatment of Opiate Dependent Patients","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2002-03","conditions":"Opioid Dependence","enrollment":1015},{"nctId":"NCT01049672","phase":"NA","title":"Diamorphine or Alfentanil for Subcutaneous Use in Hospice In-patients?","status":"COMPLETED","sponsor":"Gloucestershire Hospitals NHS Foundation Trust","startDate":"2010-09","conditions":"Cancer","enrollment":18},{"nctId":"NCT00175357","phase":"PHASE3","title":"NAOMI: A Study to Compare Medically-prescribed Heroin With Oral Methadone in Chronic Opiate Addiction","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2005-03","conditions":"Opiate Addiction","enrollment":192},{"nctId":"NCT01881802","phase":"","title":"Study of Opioid Immunosuppressive Effects","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2013-03","conditions":"Opioid Abuse or Dependence","enrollment":50},{"nctId":"NCT00880373","phase":"PHASE4","title":"Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease - Sickle With Ibuprofen & Morphine","status":"TERMINATED","sponsor":"London North West Healthcare NHS Trust","startDate":"2011-03","conditions":"Sickle Cell Disease","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":82435,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Diamorphine or Morphine","genericName":"Diamorphine or Morphine","companyName":"London North West Healthcare NHS Trust","companyId":"london-north-west-healthcare-nhs-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Diamorphine and morphine are opioid agonists that bind to mu opioid receptors in the central and peripheral nervous system to reduce pain perception and produce analgesia. Used for Moderate to severe acute pain, Chronic cancer pain, Acute myocardial infarction pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}